CAPR

SEC Filing Summary: Nile Therapeutics, Inc. (Form 8-K)

Business Context and Reporting Period

Date of Report: September 17, 2007
Company: Nile Therapeutics, Inc. (formerly SMI Products, Inc.)
Event: Completion of a reverse merger and change in control. SMI Products, Inc. merged with Nile Merger Sub., Inc. (a subsidiary of SMI) and Nile Therapeutics, Inc. ("Old Nile"). Old Nile became the surviving entity and a wholly-owned subsidiary of SMI. SMI subsequently changed its name to "Nile Therapeutics, Inc."
Business Focus: Development and commercialization of innovative products for cardiovascular and metabolic diseases. The company has no product revenues and is in the pre-revenue, development stage.

Key Financial Metrics

Revenue: $0 (No product sales to date).
Net Loss:

• Six months ended June 30, 2007: $2,237,825
• Period from inception (Aug 1, 2005) through Dec 31, 2006: $2,592,015
• Accumulated Deficit (through June 30, 2007): $4,829,840

Stockholders' Equity: ($4,817,673) as of June 30, 2007.
Recent Financing:

• September 11, 2007: Raised gross proceeds of $19,974,747 via private placement of 2,522,064 shares of Old Nile Common Stock.
• July 24, 2007: Issued $1,500,000 8% Promissory Note (repaid in full Sept 11, 2007 with $120,000 premium).
• March 28, 2006: Issued $4,000,000 in 6% Convertible Promissory Notes (converted to equity upon the September financing).

Capital Structure (Post-Merger):

• Common Stock Outstanding: 24,099,716 shares.
• Options Outstanding: 3,404,013 shares (exercise prices $0.09 - $2.71).
• Warrants Outstanding: 168,337 shares.

Liquidity: Management expects current resources to fund operations until the first quarter of 2009. Additional financing will be required thereafter.

Material Changes vs. Prior Period

• Corporate Identity: The registrant changed its name from SMI Products, Inc. to Nile Therapeutics, Inc. and adopted Nile's business plan, ceasing its prior internet real estate mortgage services business.
• Change in Control: Former holders of Old Nile Common Stock now beneficially own approximately 95% of the outstanding capital stock. The board of directors and executive management were reconstituted.
• Accounting Treatment: The merger was accounted for as an acquisition of SMI and a recapitalization of Old Nile, with Old Nile as the accounting acquirer.
• Accountant Change: The company dismissed Paritz & Co. and engaged Hays & Company, LLP as its principal accountant effective September 17, 2007.

Guidance, Outlook, and Risks

Outlook and Plan of Operation:

• CD-NP (Lead Compound): A chimeric natriuretic peptide in Phase I clinical studies for heart failure. Phase Ib studies in heart failure patients are planned for initiation in Q4 2007.
• 2NTX-99: A pre-clinical small molecule anti-atherothrombotic agent. Pre-clinical toxicology and manufacturing activities planned for Q3 2007; IND filing expected by end of 2009.
• Expenditures: Anticipated spend for 2007 includes approximately $4.5 million on clinical R&D and $1.5 million on general and administrative expenses.

Management Commentary: The company expects to incur substantial losses and negative operating cash flow for the foreseeable future. Success depends on raising additional capital, which may result in dilution to shareholders.

Material Risks:

• Going Concern: Recurring losses and negative cash flows threaten the ability to continue as a going concern without additional financing.
• Regulatory Approval: No assurance that FDA or other authorities will approve product candidates. Clinical trials may fail or be delayed.
• Intellectual Property: Reliance on license agreements with Mayo Foundation and Dr. Cesare Casagrande; failure to meet obligations could result in loss of rights.
• Internal Controls: Internal controls do not currently meet all standards of Section 404 of the Sarbanes-Oxley Act.
• Penny Stock Status: The stock is likely to be classified as a "penny stock" (price < $5.00), which may restrict trading liquidity.

Key Facts for Investor Verification

• Capital Runway: Verify if the $19.97 million raised in September 2007 is sufficient to reach the projected Q1 2009 funding milestone given the high burn rate of clinical trials.
• Clinical Milestones: Monitor the initiation and results of the Phase Ib studies for CD-NP scheduled for Q4 2007.
• Licensing Obligations: Review the specific performance milestones and royalty obligations under the Mayo Foundation and Dr. Casagrande license agreements.
• Dilution Risk: Assess the impact of the 3.4 million outstanding options and potential future equity financings on shareholder value.
• Internal Controls: Confirm the timeline and success of implementing Section 404 Sarbanes-Oxley compliance to avoid delisting or audit failures.